Investor Relations

Corporate Overview

Exscientia (Nasdaq: EXAI) uses artificial intelligence, or AI, to modernize the way new medicines are discovered and developed, aiming to deliver the best possible medicines far faster than industry standards. We have built a complete end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models and patient selection that has delivered real-world, pioneering achievements. Exscientia has developed the first-ever AI-designed drug candidates to progress into clinical trials as well as the first clinically-validated AI-driven platform to improve treatment outcomes for cancer patients prospectively, with a rapidly scaling pipeline of more than 25 projects across therapeutic areas underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Latest News

View all news